New biomarker for lung cancer detection using exosomes
Exosomal Thomsen-Friedenreich glycoantigen as a new biomarker for lung cancer screening and early detection
This study is looking at a new way to spot lung cancer early by checking for a special marker in tiny particles called exosomes, which could help make lung cancer screenings more accurate and reduce the chances of false alarms from regular scans, so patients can get the right care sooner.
Quick facts
| Grant type | R21 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | State University of New York at Buffalo NIH-funded |
| Lab location | 1 site (Amherst, United States) |
| Project ID | NIH-10670439 on NIH RePORTER |
What this research studies
This research investigates a novel biomarker, Thomsen-Friedenreich glycoantigen, found in exosomes for the early detection of lung cancer. The study aims to improve the accuracy of lung cancer screening by developing a liquid biopsy assay that can identify this biomarker in patients. By focusing on tumor-derived exosomes, the research seeks to reduce the high false-positive rates associated with traditional CT scans, thereby minimizing unnecessary invasive procedures and radiation exposure. Patients will be monitored for the presence of this biomarker to enhance early diagnosis and treatment options.
Who could benefit from this research
Good fit: Ideal candidates for this research are individuals at high risk for lung cancer, including smokers and those with a family history of the disease.
Not a fit: Patients who do not have a risk of lung cancer or those with advanced-stage cancer may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to more accurate and less invasive lung cancer screening methods.
How similar studies have performed: Other research has shown promise in using liquid biopsies for cancer detection, making this approach a potentially valuable advancement in the field.
Where this research is happening
Amherst, United States
- State University of New York at Buffalo — Amherst, United States (Active)
Researchers
- Principal investigator: Wu, Yun — State University of New York at Buffalo
- Study coordinator: Wu, Yun
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.